• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Hologic Details Environmental, Social and Governance Efforts — Including Expanded Environmental Ambitions — in New Sustainability Report

    4/22/25 8:08:00 AM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email

    Report highlights efforts to enhance access and equity in women's health and invest in the future with science-based environmental targets, employee development and community engagement

    Hologic, Inc. (NASDAQ:HOLX), a company that develops industry-leading technologies that detect, diagnose and treat life-changing health conditions that affect women, today released its annual sustainability report with an emphasis on expanded environmental commitments and efforts to advance access and equity in women's health.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422781805/en/

    Hologic 2024 Sustainability Report

    Hologic 2024 Sustainability Report

    For almost four decades, Hologic has pushed the limits of what's possible to improve women's health, and in 2024 its technologies impacted more than 193 million lives worldwide.1 As a science-based company, it has a long-standing approach to operate sustainably and responsibly.

    "We firmly believe that our success as a company is fundamentally tied to our ability and commitment to help millions of women worldwide live healthier lives," said Hologic Chairman, President and CEO Stephen P. MacMillan. "This is our reason for being. For us, women's health is more than a business; it is our purpose: to enable healthier lives everywhere, every day."

    The newly launched report covers four areas of focus reflecting the issues that directly impact Hologic's stakeholders, communities and women around the world. Below are highlights from each area in 2024:

    Advancing Women's Access and Equity in Healthcare

    • Brought innovative healthcare technologies to women globally, including through FDA clearance for the Genius™ Digital Diagnostics System2 for cervical cancer screening, the launch of Genius AI® Detection 2.03 solution for breast cancer screening and the acquisition of Endomagnetics and Gynesonics.
    • Released the fourth Hologic Global Women's Health Index in partnership with Gallup, bringing international attention to critical women's health issues based on data reflecting 97% of the global adult population.
    • Raised awareness of health issues impacting millions of women via its strategic partnership with the Women's Tennis Association (WTA) and through efforts such as the #BustTheMyth breast cancer awareness campaign and the "Better Is Possible" campaign focused on abnormal uterine bleeding, which received 7.3 million views.
    • Collaborated with health equity organizations such as the Black Women's Health Imperative and the National Alliance for Hispanic Health to support women's screening, diagnostic treatment and outreach services in communities across the U.S.
    • Launched initiatives aimed at advancing medical education within the healthcare community, including a partnership with the American Association of Gynecologic Laparoscopists (AAGL) focused on hysteroscopy, and a new project with the UK Royal College of Obstetricians and Gynaecologists to integrate technologies like AI into obstetric and gynecologic surgery.
    • Supported patient-focused programs that improve access to quality healthcare, such as the Promise Fund of Florida and Neighborhood Healthcare near Hologic's campus in San Diego.

    Protecting the Environment

    • Committed to achieving a 50% reduction in emissions by 2030 and net zero by 2050, aligned with the Science Based Targets initiative.
    • Achieved a 10% emission reduction across Scopes 1, 2 and 34 since 2020 baseline.
    • Completed Scope 3 carbon emission assessment of the full value chain and demonstrated a 10% absolute reduction and 16% reduction in emission intensity from 2020 baseline.
    • Reduced water use at key operational sites by 20% since baseline through initiatives like the Cooling Tower Water Project in San Diego and rainwater capture efforts in Costa Rica and Belgium.
    • Diverted 65% of waste from landfills, with three Hologic sites at over 90% diversion rates.

    Supporting Our People and Communities

    • Ranked in the 97th percentile of employee engagement, and 98% of employees surveyed feel Hologic's mission makes their job important, based on an annual survey conducted by Gallup.
    • Continued commitment to pay equity by maintaining a zero gender net pay gap.
    • Supported patients, communities and students by engaging with nonprofit organizations like SewHope to bring Pap tests for cervical cancer screening to women in Guatemala, sponsoring events such as the Susan G. Komen More Than Pink Walk to combat breast cancer, and engaging with students interested in STEM careers.
    • Donated $1.8M in corporate grants to support local communities in 2024.

    Operating With Integrity

    • Expanded sustainability reporting transparency aligning to the Global Reporting Initiative (GRI), the Task Force on Climate-Related Financial Disclosures (TCFD) and the Sustainability Accounting Standards Board (SASB) voluntary reporting frameworks.
    • Unveiled the company's first Cybersecurity Operations Center (SOC), a strategic hub in Costa Rica aimed at monitoring, detecting and responding to cyber threats.
    • Reinforced commitment to maintaining the highest standards of compliance and quality, with 12 Hologic sites holding ISO 13485 certifications.
    • 34% of strategic and preferred suppliers committed to science-based environmental sustainability targets.

    To read the full sustainability report, please visit www.hologic.com/sustainability.

    About Hologic, Inc.

    Hologic, Inc. is a global leader in women's health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.

    Forward-Looking Statements

    This news release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient, as the actual effect of the use of the products can only be determined on a case-by-case basis. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such data or statements are based.

    Hologic, The Science of Sure, Genius and Genius AI are trademarks and/or registered trademarks of Hologic, Inc., and/or its subsidiaries in the United States and/or other countries.

    References and Notes

    1. Lives impacted include assays, mammograms, surgical treatments and other Hologic procedures.

    2. FDA clearance followed CE Mark.

    3. Available in Europe, Australia, New Zealand and the United States.

    4. Scope 1: direct emissions; Scope 2: emissions from purchased energy; Scope 3: indirect emissions in the value chain.

    SOURCE: Hologic, Inc.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250422781805/en/

    Media Contact

    Bridget Perry

    Senior Director, Corporate Communications

    (+1) 508.263.8654

    [email protected]

    Investor Contact

    Michael Watts

    Corporate Vice President, Investor Relations

    (+1) 858.410.8514

    [email protected]

    Get the next $HOLX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    8/18/2025$80.00Hold → Buy
    Argus
    8/6/2025$87.00Sector Perform → Outperform
    RBC Capital Mkts
    7/9/2025$80.00Neutral → Buy
    Citigroup
    5/27/2025Hold
    Needham
    3/3/2025Buy → Hold
    Argus
    2/6/2025$80.00 → $75.00Outperform → Market Perform
    Leerink Partners
    2/3/2025Buy → Hold
    Needham
    12/13/2024Peer Perform
    Wolfe Research
    More analyst ratings

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hologic Announces Financial Results for Third Quarter of Fiscal 2025

    – Revenue of $1,023.8 Million Exceeds Guidance – – Company Reports GAAP Diluted EPS of $0.86; Non-GAAP Diluted EPS of $1.08 Exceeds Guidance – – In Fourth Quarter, Company Remains on Track for Solid Revenue Growth and Faster Non-GAAP EPS Growth – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal third quarter ended June 28, 2025. "We are pleased to have delivered revenue and non-GAAP earnings growth in the third quarter that exceeded our guidance ranges," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "And we made great progress toward returning to better top- and bottom-line growth in the fourth qua

    7/30/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.holog

    7/2/25 4:05:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Present New Data at ASCO 2025 Reinforcing the Practice-Changing Role of the Breast Cancer Index® Test in Helping to Deliver More Personalized Care to Patients

    Completed assessment of more than 2,800 patients highlights the profound impact of the test in helping to predict the likelihood of extended endocrine therapy benefit for patients with HR+ breast cancer to support more informed care decisions Hologic, Inc. (NASDAQ:HOLX) and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating the significant clinical impact of the Breast Cancer Index® (BCI®) test, which will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2025. "These data highlight the critical role the Breast Cancer Index test plays in guiding extended endocrine therapy decisions for women with early-stage, hormone

    5/22/25 5:05:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Div. President, GYN Surgical Schnittker Brandon covered exercise/tax liability with 69 shares, decreasing direct ownership by 1% to 6,094 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    6/3/25 4:19:30 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    New insider Liddy Anne M. claimed ownership of 11,426 shares (SEC Form 3)

    3 - HOLOGIC INC (0000859737) (Issuer)

    5/2/25 4:52:34 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    October 29, 2024 - FDA Roundup: October 29, 2024

    For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care

    February 2, 2024 - FDA Roundup: February 2, 2024

    For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

    2/2/24 3:58:21 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hologic upgraded by Argus with a new price target

    Argus upgraded Hologic from Hold to Buy and set a new price target of $80.00

    8/18/25 9:05:38 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Hologic from Sector Perform to Outperform and set a new price target of $87.00

    8/6/25 7:54:35 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic upgraded by Citigroup with a new price target

    Citigroup upgraded Hologic from Neutral to Buy and set a new price target of $80.00

    7/9/25 8:14:56 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    View All

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    CellMax Life Announces Expansion of Company Board With Leading Industry Experts

    Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

    4/6/23 9:00:00 AM ET
    $EXAS
    $HOLX
    Medical Specialities
    Health Care
    Medical Electronics

    IMPULSE DYNAMICS APPOINTS FIVE NEW BOARD MEMBERS

    MARLTON, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Impulse Dynamics N.V., a company dedicated to improving the lives of people with heart failure (HF), today announced the election of five new members to its Board of Directors at the most recent meeting of its shareholders.  "We are extremely pleased to have Jim Tobin, Joe Capper, Glenn Muir, John Bakewell, and Dan Scavila all joining our board of directors," said Prof. Shlomo Ben-Haim, Chairman of the Board and Founder of Impulse Dynamics.  "This is an illustrious group to be adding to the board, and I am extremely pleased to be welcoming and working with all of them as we rapidly advance our goals for the company, for CCM therapy, and mo

    11/11/21 7:26:31 PM ET
    $BEAT
    $GMED
    $GTHX
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Medical Electronics

    $HOLX
    Financials

    Live finance-specific insights

    View All

    Hologic Announces Financial Results for Third Quarter of Fiscal 2025

    – Revenue of $1,023.8 Million Exceeds Guidance – – Company Reports GAAP Diluted EPS of $0.86; Non-GAAP Diluted EPS of $1.08 Exceeds Guidance – – In Fourth Quarter, Company Remains on Track for Solid Revenue Growth and Faster Non-GAAP EPS Growth – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal third quarter ended June 28, 2025. "We are pleased to have delivered revenue and non-GAAP earnings growth in the third quarter that exceeded our guidance ranges," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "And we made great progress toward returning to better top- and bottom-line growth in the fourth qua

    7/30/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Announce Financial Results for the Third Quarter of Fiscal 2025 on Wednesday, July 30, 2025

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2025 on Wednesday, July 30, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing (866) 400-0049 (in the United States and Canada) or +1 (313) 209-4906 (for international callers) and referencing access code 5212316. Participants may also click here to join. Participants should dial in 5-10 minutes before the call begins. Hologic will provide a live and webcast replay of the call on the Company's website at investors.holog

    7/2/25 4:05:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for Second Quarter of Fiscal 2025

    – Revenue of $1,005.3 Million Slightly Exceeds Guidance – – Company Reports GAAP Diluted EPS of ($0.08); Non-GAAP Diluted EPS of $1.03 at High End of Guidance – – Company Maintains Annual Revenue Guidance, Lowers Guidance for GAAP and Non-GAAP EPS – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal second quarter ended March 29, 2025. "We delivered on our financial commitments in the second quarter," said Stephen P. MacMillan, the Company's Chairman, President and Chief Executive Officer. "Both revenue and non-GAAP EPS finished at the high ends of our guidance ranges, driven by our diagnostics and skeletal businesses, strong profitability, share

    5/1/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    SEC Filings

    View All

    SEC Form 10-Q filed by Hologic Inc.

    10-Q - HOLOGIC INC (0000859737) (Filer)

    7/31/25 7:39:05 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HOLOGIC INC (0000859737) (Filer)

    7/30/25 4:01:45 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - HOLOGIC INC (0000859737) (Filer)

    7/18/25 8:15:41 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hologic Inc.

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    11/14/24 1:28:29 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Hologic Inc.

    SC 13G - HOLOGIC INC (0000859737) (Subject)

    2/14/24 10:04:34 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    2/9/23 11:22:19 AM ET
    $HOLX
    Medical Electronics
    Health Care